Endocrine Abstracts

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.Patients: There were 342 women (85%), the median ag...

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

Refractory or severe hypercalcemia is important clinical problem as it can lead to serious complications such as arrhythmias, acute or chronic pancreatitis, gastric ulcer, water and electrolyte balance disturbances, osteoporosis, psychoses and even to hypercalcemic crisis. Most often it is diagnosed in parathyroid cancer (PC). It is also observed in benign primary hyperparathyroidism (HPTH) in case of difficulties with adenoma’s localization. Routinely treatment includes ...

The routine use of adjuvant RAI treatment in low-risk DTC remains controversial due to the lack of unequivocal evidences of its effectiveness in radically operated subjects. The aim of the study was a retrospective evaluation of long-term outcomes of combined DTC treatment to evaluate the impact of adjuvant RAI therapy in the low risk group. Primary hypothesis was: ‘if adjuvant RAI treatment was unnecessary, a delay in RAI administration would have no impact on long-term ...

Introduction: Reliable prognostic factors are crucial to choose the optimal treatment strategy and follow-up for differentiated thyroid carcinomas (DTC) patients. Thus, the aim of the study was a retrospective evaluation of prognostic factors of cancer relapse in patients treated in a single institution.Material: The study group consisted of 510 DTC patients, staged pT1b-T4N0-N1M0, treated with total thyroidectomy followed by complementary 131...

Introduction: To date, only four tyrosine kinase inhibitors (TKIs) have demonstrated beneficial effect on progression free survival in advanced medullary thyroid cancer (MTC; vandetanib and cabozantinib) andradioiodine-refractory differentiated thyroid cancer (RR-DTC; sorafenib and lenvatinib). However, there is still lack of unequivocal proofs of their significant impact on overall survival. Therefore, treatment-related side effects and their potential impact on quality of li...

Background: Differentiated thyroid carcinoma (DTC) in children is a rare cancer, occurring in 1/100,000 children/year. In the adults a steady increase in the incidence and change in presentation of DTC has been observed over the past 30 years.Purpose: Evaluation of changes in the clinical presentation of paediatric DTC on the example of children treated in Institute of Oncology in Gliwice between 1970 and 2015.Material and methods:...